| |
Technology
Gene Activated Matrix Technology Platform
TRC’s proprietary Gene Activated Matrix™ technology
platform is designed to provide a therapeutic level of protein synthesis at a
specific site in the body and can be used in soft tissue such as skin, ligament,
tendons and cartilage, as well as in hard tissue such as bone. The technology
is distinctive in that it is immobilized gene delivery that allows for localized
control of gene uptake. The Gene Activated Matrix comprises any biocompatible
matrix containing a gene or DNA vector encoding for a growth factor or any therapeutic
protein. The gene and the matrix can be varied depending on the therapeutic target.
The technology allows for a broad spectrum of formulations and the use of any
biocompatible matrix, natural or synthetic, which would include, but not be limited
to, collagen, demineralized bone, allograft and other synthetic graft
materials.
 |
|
TRC studies have shown that proliferative cells migrate
into the Gene Activated Matrix and then take up the immobilized gene resulting
in localized and sustained production of micro quantities of growth factor proteins
or other therapeutic proteins based on the gene of choice. Compared with current
protein therapy, which may be limited due to the inherent short half-life of
a protein once administered into the human body, TRC believes that the localized
and sustained production of micro-quantities of DNA-driven proteins at the injury
site within a Gene Activated Matrix offers the opportunity to significantly enhance
the availability of therapeutic proteins to the cells performing tissue repair.
|
|
